Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone
- PMID: 10836660
- DOI: 10.1080/13625180008500375
Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone
Erratum in
- Eur J Contracept Reprod Health Care 2001 Mar;6(1):63
Abstract
Objective: To assess the contraceptive reliability, cycle control and tolerability of a new monophasic oral contraceptive containing 30 g ethinylestradiol plus 3 mg drospirenone (Yasmin, Schering AG, Berlin, Germany), it was compared with an established oral contraceptive containing 30 g ethinylestradiol plus 150 g desogestrel (Marvelon, NV Organon, Oss, The Netherlands).
Methods: A randomized, open-label, 13-cycle study was performed at 80 European centers. Contraceptive reliability, cycle control, blood pressure, body weight, the incidence of adverse events and skin condition were assessed during 13 cycles of oral contraceptive use, and at follow-up. Subjects recorded body weight on three consecutive days pretreatment and weekly thereafter.
Results: Of 2069 women who started the study and received the trial preparations in a ratio of 4:1 (ethinylestradiol/drospirenone, n = 1657; ethinylestradiol/desogestrel, n = 412), 1615 completed the 13 cycles plus follow-up, providing data for over 23,000 evaluable cycles. Eleven pregnancies occurred during treatment, only one of which (in the ethinylestradiol/drospirenone group) could not be ascribed to user failure or interaction with other factors. Both preparations provided effective contraception and cycle control. Pre-existing acne and seborrhea were improved and blood pressure was essentially unchanged. The two treatments differed in their effect on body weight, the difference being statistically significant. In the ethinylestradiol/drospirenone group, there was a distinct decrease over the whole treatment phase, while a subtle and less distinct decrease was documented in the ethinylestradiol/desogestrel group.
Conclusions: The combination of 30 g ethinylestradiol/3 mg drospirenone provides effective oral contraception, excellent cycle control, good tolerability and a level of weight loss that may have a significant beneficial effect on compliance in women with a tendency to weight gain due to water retention.
Similar articles
-
A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel.Eur J Contracept Reprod Health Care. 2000 Jun;5(2):124-34. doi: 10.1080/13625180008500387. Eur J Contracept Reprod Health Care. 2000. PMID: 10943575 Clinical Trial.
-
Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene.Eur J Contracept Reprod Health Care. 1998 Sep;3(3):113-20. doi: 10.3109/13625189809051413. Eur J Contracept Reprod Health Care. 1998. PMID: 9853201 Clinical Trial.
-
The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.Eur J Contracept Reprod Health Care. 2000 Dec;5 Suppl 3:25-33. Eur J Contracept Reprod Health Care. 2000. PMID: 11246599 Review.
-
Multicenter study of the efficacy, cycle control and tolerability of a phasic desogestrel-containing oral contraceptive.Eur J Contracept Reprod Health Care. 2000 Mar;5(1):35-45. doi: 10.1080/13625180008500378. Eur J Contracept Reprod Health Care. 2000. PMID: 10836661 Clinical Trial.
-
[Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].Minerva Ginecol. 2007 Aug;59(4):415-25. Minerva Ginecol. 2007. PMID: 17923832 Review. Italian.
Cited by
-
Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.Clin Drug Investig. 2010;30(5):325-36. doi: 10.2165/11535450-000000000-00000. Clin Drug Investig. 2010. PMID: 20384388 Clinical Trial.
-
Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder.Int J Womens Health. 2010 Aug 9;1:85-95. doi: 10.2147/ijwh.s4338. Int J Womens Health. 2010. PMID: 21072278 Free PMC article.
-
Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials.Clin Drug Investig. 2009;29(2):73-8. doi: 10.2165/0044011-200929020-00001. Clin Drug Investig. 2009. PMID: 19133702 Review.
-
Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol.Ther Clin Risk Manag. 2007 Aug;3(4):585-90. Ther Clin Risk Manag. 2007. PMID: 18472980 Free PMC article.
-
New and emerging contraceptives: a state-of-the-art review.Int J Womens Health. 2014 Feb 19;6:221-34. doi: 10.2147/IJWH.S46811. eCollection 2014. Int J Womens Health. 2014. PMID: 24570597 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources